셀트리온, 유럽서 옴리클로 점유율 30% 달성…신규 제품 판매 확대

Resumen del corpus

Celltrion achieved a 30% market share for the drug Omyclo in the European market in the second quarter, with the new product Aptozma also showing growth. The company is expanding sales of new biopharmaceuticals like Omyclo and Aptozma in Europe, driven by increased market share and successful bidding for new products. Furthermore, Celltrion is strengthening its strategy through local bidding and sales to medical institutions to boost the sales ratio of newer product groups to 70%.